California Assembly Bill AB1027

California 2025-2026 Regular Session

• Introduced: 2/20/25
• Refer: 3/28/25
• Report Pass: 3/28/25
• Refer: 4/1/25
• Report Pass: 4/29/25
• Refer: 4/29/25
• Refer: 5/14/25
• Report Pass: 5/23/25
• Engrossed: 6/2/25
• Refer: 6/3/25
• Refer: 6/11/25
• Report Pass: 6/18/25
• Refer: 6/18/25
• Report Pass: 7/14/25
• Refer: 7/14/25
• Refer: 8/18/25

Caption

An act to amend Sections 26039.

Impact

The proposed changes will significantly impact the existing cannabis regulations found in the Business and Professions Code by amending sections related to quality assurance and testing protocols. Licensees will be required to permit the department access to their cannabis products for off-the-shelf laboratory testing, a move that could enhance public safety but may also place additional operational burdens on cannabis businesses. The amendment to require proper records of quality assurance reviews in a track and trace system will further ensure accountability in the distribution of cannabis products, which could deter the sale of untested or substandard products.

Summary

Assembly Bill 1027, introduced by Assembly Member Sharp-Collins, aims to amend existing laws concerning the testing and quality assurance of cannabis products within California. The bill specifies that all cannabis and cannabis products will be subject to testing or retesting as mandated by state regulations. This initiative seeks to enhance the safety and quality of cannabis available to consumers by ensuring compliance with stringent testing standards set forth by the Department of Cannabis Control. Notably, it also requires licensed retailers to provide a certificate of analysis to customers upon request, ensuring transparency regarding the cannabis products being sold.

Sentiment

The sentiment surrounding AB 1027 appears largely supportive among legislative members advocating for consumer protection and improved public health standards in the cannabis industry. However, there may be some concerns from business owners regarding the potential financial burden and logistical challenges the new regulations may impose. Consequently, while the bill aims to advance quality assurance in the industry, it also raises questions about its implications for business operations and compliance costs.

Contention

Some notable points of contention addressed in the bill include the change from a requirement for physical tagging of embargoed cannabis products to a system that requires identification of the product without tags. This shift could lead to disputes over compliance and could challenge the effectiveness of existing processes for identifying regulated products. Moreover, the elimination of the quality assurance compliance monitor's role in conducting random reviews—replaced by department-led reviews—might be viewed as a double-edged sword, ensuring more centralized oversight but potentially reducing the frequency and unpredictability of checks that encourage compliance among licensees.